This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salahifar, H. Articles by Martin, J. L. Search for Related Content PubMed PubMed Citation Articles by Salahifar, H. Articles by Martin, J. L.

Insulin-like Growth Factor Binding Protein (IGFBP)-3 Protease Activity Secreted by MCF-7 Breast Cancer Cells: Inhibition by IGFs Does Not Require IGF-IGFBP Interaction¹

Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia

Address all correspondence and requests for reprints to: Janet Martin, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales 2065. E-mail: janetlm{at}med.su.oz.au

The proliferative action of insulin-like growth factors (IGFs) on breast cancer cells is regulated by IGF binding proteins (IGFBPs). This study characterizes the proteolysis of IGFBP-3 by an enzyme secreted by MCF-7 human breast cancer cells. Proteolysis of IGFBP-3 by incubation at 37 C with serum-free medium from MCF-7 cells was maximal at pH 5.0–5.5, with no activity detected below pH 4.5. This enzyme activity resulted in the disappearance of the 40- to 45- and 30-kDa bands of pure plasma-derived IGFBP-3, detectable by immunoblotting after SDS-PAGE, and the appearance of a single 21-kDa immunoreactive species. The 21-kDa protein did not bind IGF-I or IGF-II by ligand blotting. The enzyme activity appeared at 25- to 30-kDa by gel chromatography at pH 6.5 and was inhibited by EDTA and leupeptin, an inhibitor of cysteine and serine proteases, but not by the serine protease inhibitors aprotinin and benzamidine. IGFBP-3 protease activity was inhibited in medium conditioned by cells incubated with 50 ng/ml IGF-I. A similar inhibitory effect was seen under cell-free conditions by adding IGF-I to medium harvested from cells incubated without IGFs. The cell-free inhibition of IGFBP-3 proteolysis by IGFs did not require IGF interaction with the binding protein, because [long Arg³]IGF-I, which binds to IGFBP-3 with less than 0.2% of the potency of IGF-I, inhibited IGFBP-3 proteolysis with 20% of the potency of IGF-I. These results suggest that IGFs may regulate their own activity in breast cancer cells, preventing IGFBP-3 proteolysis by a mechanism that is not receptor mediated and does not require IGF-IGFBP interaction.

This article has been cited by other articles:

				P. W. Parodi Dairy Product Consumption and the Risk of Breast Cancer J. Am. Coll. Nutr., December 1, 2005; 24(suppl_6): 556S - 568S. [Abstract] [Full Text] [PDF]

				M. Grohmann, E. Foulstone, G. Welsh, J. Holly, J. Shield, E. Crowne, and C. Stewart Isolation and validation of human prepubertal skeletal muscle cells: maturation and metabolic effects of IGF-I, IGFBP-3 and TNF{alpha} J. Physiol., October 1, 2005; 568(1): 229 - 242. [Abstract] [Full Text] [PDF]

				C. F. Singer, M. Mogg, W. Koestler, M. Pacher, E. Marton, E. Kubista, and M. Schreiber Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions: Free IGF-II Is Correlated with Breast Cancer Size Clin. Cancer Res., June 15, 2004; 10(12): 4003 - 4009. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				H. Matsui and T. Takahashi Mouse Testicular Leydig Cells Express Klk21, a Tissue Kallikrein That Cleaves Fibronectin and IGF-Binding Protein-3 Endocrinology, November 1, 2001; 142(11): 4918 - 4929. [Abstract] [Full Text] [PDF]

				H. Salahifar, R. C. Baxter, and J. L. Martin Differential Regulation of Insulin-Like Growth Factor-Binding Protein-3 Protease Activity in MCF-7 Breast Cancer Cells by Estrogen and Transforming Growth Factor-{beta}1 Endocrinology, September 1, 2000; 141(9): 3104 - 3110. [Abstract] [Full Text] [PDF]

				R. C. Baxter Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E967 - E976. [Abstract] [Full Text] [PDF]

				J. A. Coverley, J. L. Martin, and R. C. Baxter The Effect of Phosphorylation by Casein Kinase 2 on the Activity of Insulin-Like Growth Factor-Binding Protein-3 Endocrinology, February 1, 2000; 141(2): 564 - 570. [Abstract] [Full Text] [PDF]

				J. L. Martin and R. C. Baxter Oncogenic ras Causes Resistance to the Growth Inhibitor Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) in Breast Cancer Cells J. Biol. Chem., June 4, 1999; 274(23): 16407 - 16411. [Abstract] [Full Text] [PDF]

				C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]

				Z. Shi, W. Xu, F. Loechel, U. M. Wewer, and L. J. Murphy ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., June 9, 2000; 275(24): 18574 - 18580. [Abstract] [Full Text] [PDF]